Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Bitwise revealed in the S-1 update file its plan to waive fees for Ethereum spot ETFs for a limited time

Bitwise revealed in the S-1 update file its plan to waive fees for Ethereum spot ETFs for a limited time

Bitget2024/07/04 00:37

PANews reported on July 4th, according to Cointelegraph, in the documents submitted to the U.S. Securities and Exchange Commission on July 3rd, Bitwise has amended its Ethereum spot ETF's S-1 registration statement in advance, which includes waiving the sponsorship fees for the first $500 million trust assets within the past six months. The document does not include a specific launch date for listing and trading on the New York Stock Exchange Arca but indicates that it will start "as soon as possible" after the registration effective date.

Earlier today, Bloomberg analyst James Seyffart commented on Bitwise's resubmitted revised Ethereum ETF S-1 form stating that an Ethereum spot ETF product might be listed later next week or during the week of July 15th.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "copper rush" cools off? LME sees the largest delivery in nearly four weeks, copper price retreats to $14,000

Copper prices have stabilized around $14,000 per ton after previously falling, as exchange-tracked warehouses have experienced a new round of inventory deliveries, indicating that the supply shortage has somewhat eased.

智通财经2026/09/15 04:01
The "copper rush" cools off? LME sees the largest delivery in nearly four weeks, copper price retreats to $14,000

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage